Why ketamine.
Established status epilepticus
NMDA receptor
Neuroprotection
Pharmacokinetics
Journal
Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
15
11
2022
revised:
19
12
2022
accepted:
20
12
2022
pmc-release:
01
04
2024
medline:
4
4
2023
pubmed:
8
1
2023
entrez:
7
1
2023
Statut:
ppublish
Résumé
We present the rationale for testing ketamine as an add-on therapy for treating benzodiazepine refractory (established) status epilepticus. In animal studies, ketamine terminates benzodiazepine refractory status epilepticus by interfering with the pathophysiological mechanisms and is a neuroprotectant. Ketamine does not suppress respiration when used for sedation and anesthesia. A Series of reports suggest that ketamine can help terminate refractory and super refractory status epilepticus. We propose to use 1 or 3 mg/Kg ketamine intravenously based on animal-to-human conversion and pharmacokinetic studies. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022.
Identifiants
pubmed: 36609129
pii: S1525-5050(22)00515-7
doi: 10.1016/j.yebeh.2022.109066
pmc: PMC10073319
mid: NIHMS1860641
pii:
doi:
Substances chimiques
Ketamine
690G0D6V8H
Anticonvulsants
0
Benzodiazepines
12794-10-4
Neuroprotective Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
109066Subventions
Organisme : NINDS NIH HHS
ID : R01 NS040337
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS120945
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JK and TBP serve on a Data Safety Monitoring Board of a status epilepticus treatment clinical trial sponsored by Marinus Pharmaceuticals. LC, ESR, TPB JE, JC, JC, SS, RS, and JK receive grant support from NIH.
Références
Neurobiol Dis. 2017 Jul;103:45-53
pubmed: 28377128
Lancet. 2019 May 25;393(10186):2135-2145
pubmed: 31005386
Epilepsia. 2013 Aug;54(8):1498-503
pubmed: 23758557
J Neurosci. 2008 Jan 9;28(2):376-84
pubmed: 18184780
Acad Emerg Med. 1998 Oct;5(10):971-6
pubmed: 9862587
Neurology. 2020 Oct 20;95(16):e2286-e2294
pubmed: 32873691
Ann Neurol. 2014 Feb;75(2):178-85
pubmed: 24318290
Epilepsia. 2017 Mar;58(3):494-504
pubmed: 28452419
Mol Pharmacol. 2013 Jul;84(1):1-11
pubmed: 23585058
Acad Emerg Med. 2000 Mar;7(3):278-81
pubmed: 10730837
Epilepsia. 1995 Feb;36(2):186-95
pubmed: 7821277
Neurobiol Dis. 2013 Jun;54:225-38
pubmed: 23313318
Neurosci Lett. 1999 Apr 23;265(3):187-90
pubmed: 10327162
Arch Neurol. 2010 Aug;67(8):931-40
pubmed: 20697043
Epilepsy Res. 2004 Mar;59(1):43-50
pubmed: 15135166
Epilepsia. 2016 Sep;57(9):1406-15
pubmed: 27500978
Ann Neurol. 2012 Jul;72(1):91-102
pubmed: 22829271
N Engl J Med. 2012 Feb 16;366(7):591-600
pubmed: 22335736
Ann Emerg Med. 2009 Aug;54(2):171-80.e1-4
pubmed: 19501426
JAMA Neurol. 2018 Apr 1;75(4):410-418
pubmed: 29356811
Pediatr Crit Care Med. 2016 Dec;17(12):1109-1116
pubmed: 27505716
Epilepsy Behav. 2005 Dec;7 Suppl 3:S3-11
pubmed: 16278099
Epilepsia Open. 2018 Nov 02;3(Suppl Suppl 2):165-168
pubmed: 30564775
Brain Res. 1998 Jan 26;782(1-2):240-7
pubmed: 9519269
Epilepsia. 2015 Oct;56(10):1515-23
pubmed: 26336950
N Engl J Med. 2019 Nov 28;381(22):2103-2113
pubmed: 31774955
J Clin Neurophysiol. 1995 Jul;12(4):326-42
pubmed: 7560021
Neurology. 2012 Nov 27;79(22):2180-6
pubmed: 23136262
Am J Emerg Med. 2008 Nov;26(9):985-1028
pubmed: 19091264
Epilepsy Curr. 2016 Jan-Feb;16(1):48-61
pubmed: 26900382
Epilepsy Res. 2000 Dec;42(2-3):117-22
pubmed: 11074184
Lancet. 2019 May 25;393(10186):2125-2134
pubmed: 31005385
Pharmacotherapy. 2019 Apr;39(4):454-462
pubmed: 30825333
N Engl J Med. 2001 Aug 30;345(9):631-7
pubmed: 11547716
J Neurosci. 2005 Aug 24;25(34):7724-33
pubmed: 16120773
Ann Neurol. 2002 Feb;51(2):175-81
pubmed: 11835373
Anesthesiology. 1986 Nov;65(5):492-9
pubmed: 3777478
Epilepsia. 2019 Mar;60(3):373-380
pubmed: 30785224
Ann Emerg Med. 2011 May;57(5):449-61
pubmed: 21256625
Pharmaceuticals (Basel). 2022 Oct 21;15(10):
pubmed: 36297409
J Neurosci. 2008 Mar 5;28(10):2527-38
pubmed: 18322097
Neurology. 2012 Aug 28;79(9):871-7
pubmed: 22843278
J Neurosci. 1997 Oct 1;17(19):7532-40
pubmed: 9295398
Epilepsia. 1994 Jan-Feb;35(1):27-34
pubmed: 8112254
Epilepsia. 2007;48 Suppl 5:109-13
pubmed: 17910589
Epilepsia. 2008 Feb;49(2):248-55
pubmed: 17941842
Epilepsy Res. 1990 Mar;5(2):103-11
pubmed: 2158437
Lancet. 2020 Apr 11;395(10231):1217-1224
pubmed: 32203691
Lancet Neurol. 2006 Mar;5(3):246-56
pubmed: 16488380